文献速递支持与姑息治疗

遗传小鼠模型重现ICI相关心肌炎并支持机制导向治疗干预

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
PubMed 文献 · Cancer Discov · 2020-11-30

该研究建立了一个ICI相关心肌炎的临床前小鼠模型,在Pdcd1完全缺失背景下Ctla4单等位缺失导致约半数小鼠过早死亡,死亡由T细胞和巨噬细胞心肌浸润及严重心电图异常引起, closely recapitulating患者中ICI相关心肌炎的临床和病理特征。利用该模型,研究者证明Ctla4和Pdcd1以基因剂量依赖方式功能性相互作用,为联合ICI治疗时心肌炎发生率增加提供了机制,并显示CTLA4-Ig(abatacept)干预足以改善疾病进展,且提供了一系列abatacept减轻ICI心肌炎暴发过程的患者病例。

要点

  • Ctla4单等位缺失合并Pdcd1完全缺失可致约半数小鼠因心肌炎过早死亡。
  • Ctla4与Pdcd1以基因剂量依赖方式功能性相互作用,解释联合ICI治疗心肌炎风险增加。
  • CTLA4-Ig(abatacept)干预可改善小鼠心肌炎进展,并在患者病例系列中减轻暴发性病程。

核心结论

  • 该临床前小鼠模型重现了ICI相关心肌炎的临床和病理特征,并支持CTLA4-Ig(abatacept)作为机制导向的治疗干预。

研究设计与样本

  • 研究采用在Pdcd1完全遗传缺失背景下Ctla4单等位缺失的遗传小鼠模型,并辅以abatacept干预实验及患者病例系列。

主要发现

  • 在Pdcd1完全缺失背景下Ctla4单等位缺失导致约半数小鼠过早死亡,死亡由T细胞和巨噬细胞心肌浸润及严重心电图异常引起。
  • Ctla4和Pdcd1以基因剂量依赖方式功能性相互作用,为联合ICI治疗时心肌炎发生频率增加提供机制。
  • CTLA4-Ig(abatacept)干预足以改善小鼠疾病进展,并在患者病例系列中减轻ICI心肌炎的暴发过程。

临床怎么用

  • 该模型和机制证据支持在ICI相关心肌炎中开展以CTLA4-Ig(abatacept)为干预的临床治疗研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis. Here, we report a robust preclinical mouse model of ICI-associated myocarditis in which monoallelic loss of Ctla4 in the context of complete genetic absence of Pdcd1 leads to premature death in approximately half of mice. Premature death results from myocardial infiltration by T cells and macrophages and severe ECG abnormalities, closely recapitulating the clinical and pathologic hallmarks of ICI-associated myocarditis observed in patients. Using this model, we show that Ctla4 and Pdcd1 functionally interact in a gene dosage-dependent manner, providing a mechanism by which myocarditis arises with increased frequency in the setting of combination ICI therapy. We demonstrate that intervention with CTLA4-Ig (abatacept) is sufficient to ameliorate disease progression and additionally provide a case series of patients in which abatacept mitigates the fulminant course of ICI myocarditis. SIGNIFICANCE: We provide a preclinical model of ICI-associated myocarditis which recapitulates this clinical syndrome. Using this model, we demonstrate that CTLA4 and PD-1 (ICI targets) functionally interact for myocarditis development and that intervention with CTLA4-Ig (abatacept) attenuates myocarditis, providing mechanistic rationale and preclinical support for therapeutic clinical studies.See related commentary by Young and Bluestone, p. 537.This article is highlighted in the In This Issue feature, p. 521.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Wei SC, Meijers WC, Axelrod ML, et al. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov. 2020. PMID: 33257470. doi:10.1158/2159-8290.CD-20-0856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。